Fig. 3: HMPL-013 inhibits CNV-induced VEGF and VEGFR2 binding in choroidal vascular endothelial cells and macrophages. | Cell Death & Disease

Fig. 3: HMPL-013 inhibits CNV-induced VEGF and VEGFR2 binding in choroidal vascular endothelial cells and macrophages.

From: Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells and M1-type macrophages to protect against mouse laser-induced choroidal neovascularization

Fig. 3

The mice were randomly divided into four group: normal, CNV 7 d, CNV 7 d + DMSO, and CNV 7 d + HMPL-013. a Western blot was done to detect VEGF, p-VEGFR2, and VEGFR2 in retina–RPE–choroid complex tissues. b Densitometry values of VEGF and VEGFR2 normalized to GAPDH. ***P < 0.005 vs. normal group; ##P < 0.01 vs. CNV 7 d group. c Co-immunoprecipitation (Co-IP) was done to detect the interaction between VEGF and p-VEGFR2 in retina–RPE–choroid complex tissues using anti-p-VEGFR2 antibody as the bait. d Co-IP was done to detect the interaction between VEGF and p-VEGFR2 in retina–RPE–choroid complex tissues using anti-VEGF antibody as the bait. e Immunostaining of p-VEGFR2 (red), VEGF (green), and DAPI (blue) on retina–RPE–choroid cryosections. f Immunostaining of CD31 (endothelial cell marker, red), p-VEGFR2 (blue), and DAPI (blue) on choroidal flat mounts. g Immunostaining of IBA-1 (macrophage marker, red), p-VEGFR2 (blue), and DAPI (blue) on choroidal flat mounts. n = 10 in each group.

Back to article page